AstraZeneca (LON:AZN) Given “Buy” Rating at Jefferies Financial Group

AstraZeneca (LON:AZN)‘s stock had its “buy” rating restated by equities researchers at Jefferies Financial Group in a research note issued on Monday,Digital Look reports. They currently have a £150 target price on the biopharmaceutical company’s stock. Jefferies Financial Group’s price target would indicate a potential upside of 14.50% from the company’s previous close.

AZN has been the subject of several other research reports. Shore Capital reiterated a “buy” rating and issued a £145 price objective on shares of AstraZeneca in a report on Thursday. JPMorgan Chase & Co. reissued an “overweight” rating on shares of AstraZeneca in a research report on Monday, October 13th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a £110 target price on shares of AstraZeneca in a report on Wednesday, July 30th. Finally, Berenberg Bank upped their target price on shares of AstraZeneca from £142 to £145 and gave the stock a “buy” rating in a research note on Tuesday, October 21st. Four investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of £138.

AstraZeneca Price Performance

AZN opened at £131 on Monday. The company has a debt-to-equity ratio of 73.83, a current ratio of 0.93 and a quick ratio of 0.59. AstraZeneca has a 1 year low of GBX 9,573.51 and a 1 year high of £131.06. The firm has a market cap of £203.08 billion, a price-to-earnings ratio of 24.67, a PEG ratio of 0.86 and a beta of 0.17. The stock’s 50 day simple moving average is £121.57 and its 200 day simple moving average is £112.42.

Insider Transactions at AstraZeneca

In other AstraZeneca news, insider Aradhana Sarin sold 9,563 shares of the company’s stock in a transaction dated Thursday, August 14th. The stock was sold at an average price of £115.12, for a total value of £1,100,892.56. Corporate insiders own 0.15% of the company’s stock.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.